Lower respiratory tract infection caused by respiratory syncytial virus: Current management and new therapeutics

Natalie I. Mazur; Federico Martinón-Torres; Eugenio Baraldi; Brigitte Fauroux; Anne Greenough; Terho Heikkinen; Paolo Manzoni; Asuncion Mejias; Harish Nair; Nikolaos G. Papadopoulos; Fernando P. Polack; Octavio Ramilo; Mike Sharland; Renato Stein; Shabir A. Madhi; Louis Bont

doi:10.1016/S2213-2600(15)00255-6

Lower respiratory tract infection caused by respiratory syncytial virus: Current management and new therapeutics

Natalie I. Mazur, Federico Martinón-Torres, Eugenio Baraldi, Brigitte Fauroux, Anne Greenough, Terho Heikkinen, Paolo Manzoni, Asuncion Mejias, Harish Nair, Nikolaos G. Papadopoulos, Fernando P. Polack, Octavio Ramilo, Mike Sharland, Renato Stein, Shabir A. Madhi, Louis Bont^*

^*Corresponding author for this work

Research output: Contribution to journal › Literature review › peer-review

234 Citations (Scopus)

Abstract

Respiratory syncytial virus (RSV) is a major worldwide cause of morbidity and mortality in children under five years of age. Evidence-based management guidelines suggest that there is no effective treatment for RSV lower respiratory tract infection (LRTI) and that supportive care, ie, hydration and oxygenation, remains the cornerstone of clinical management. However, RSV treatments in development in the past decade include 10 vaccines and 11 therapeutic agents in active clinical trials. Maternal vaccination is particularly relevant because the most severe disease occurs within the first 6 months of life, when children are unlikely to benefit from active immunisation. We must optimise the implementation of novel RSV therapeutics by understanding the target populations, showing safety, and striving for acceptable pricing in the context of this worldwide health problem. In this Review, we outline the limitations of RSV LRTI management, the drugs in development, and the remaining challenges related to study design, regulatory approval, and implementation.

Original language	English
Pages (from-to)	888-900
Number of pages	13
Journal	The Lancet Respiratory Medicine
Volume	3
Issue number	11
DOIs	https://doi.org/10.1016/S2213-2600(15)00255-6
Publication status	Published - Nov 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S2213-2600(15)00255-6

Cite this

Mazur, N. I., Martinón-Torres, F., Baraldi, E., Fauroux, B., Greenough, A., Heikkinen, T., Manzoni, P., Mejias, A., Nair, H., Papadopoulos, N. G., Polack, F. P., Ramilo, O., Sharland, M., Stein, R., Madhi, S. A., & Bont, L. (2015). Lower respiratory tract infection caused by respiratory syncytial virus: Current management and new therapeutics. The Lancet Respiratory Medicine, 3(11), 888-900. https://doi.org/10.1016/S2213-2600(15)00255-6

@article{8009c7ea434046bb928eb477048b73d8,

title = "Lower respiratory tract infection caused by respiratory syncytial virus: Current management and new therapeutics",

abstract = "Respiratory syncytial virus (RSV) is a major worldwide cause of morbidity and mortality in children under five years of age. Evidence-based management guidelines suggest that there is no effective treatment for RSV lower respiratory tract infection (LRTI) and that supportive care, ie, hydration and oxygenation, remains the cornerstone of clinical management. However, RSV treatments in development in the past decade include 10 vaccines and 11 therapeutic agents in active clinical trials. Maternal vaccination is particularly relevant because the most severe disease occurs within the first 6 months of life, when children are unlikely to benefit from active immunisation. We must optimise the implementation of novel RSV therapeutics by understanding the target populations, showing safety, and striving for acceptable pricing in the context of this worldwide health problem. In this Review, we outline the limitations of RSV LRTI management, the drugs in development, and the remaining challenges related to study design, regulatory approval, and implementation.",

author = "Mazur, {Natalie I.} and Federico Martin{\'o}n-Torres and Eugenio Baraldi and Brigitte Fauroux and Anne Greenough and Terho Heikkinen and Paolo Manzoni and Asuncion Mejias and Harish Nair and Papadopoulos, {Nikolaos G.} and Polack, {Fernando P.} and Octavio Ramilo and Mike Sharland and Renato Stein and Madhi, {Shabir A.} and Louis Bont",

year = "2015",

month = nov,

doi = "10.1016/S2213-2600(15)00255-6",

language = "English",

volume = "3",

pages = "888--900",

journal = "The Lancet Respiratory Medicine",

issn = "2213-2600",

publisher = "Elsevier Ltd",

number = "11",

}

Mazur, NI, Martinón-Torres, F, Baraldi, E, Fauroux, B, Greenough, A, Heikkinen, T, Manzoni, P, Mejias, A, Nair, H, Papadopoulos, NG, Polack, FP, Ramilo, O, Sharland, M, Stein, R, Madhi, SA & Bont, L 2015, 'Lower respiratory tract infection caused by respiratory syncytial virus: Current management and new therapeutics', The Lancet Respiratory Medicine, vol. 3, no. 11, pp. 888-900. https://doi.org/10.1016/S2213-2600(15)00255-6

TY - JOUR

T1 - Lower respiratory tract infection caused by respiratory syncytial virus

T2 - Current management and new therapeutics

AU - Mazur, Natalie I.

AU - Martinón-Torres, Federico

AU - Baraldi, Eugenio

AU - Fauroux, Brigitte

AU - Greenough, Anne

AU - Heikkinen, Terho

AU - Manzoni, Paolo

AU - Mejias, Asuncion

AU - Nair, Harish

AU - Papadopoulos, Nikolaos G.

AU - Polack, Fernando P.

AU - Ramilo, Octavio

AU - Sharland, Mike

AU - Stein, Renato

AU - Madhi, Shabir A.

AU - Bont, Louis

PY - 2015/11

Y1 - 2015/11

N2 - Respiratory syncytial virus (RSV) is a major worldwide cause of morbidity and mortality in children under five years of age. Evidence-based management guidelines suggest that there is no effective treatment for RSV lower respiratory tract infection (LRTI) and that supportive care, ie, hydration and oxygenation, remains the cornerstone of clinical management. However, RSV treatments in development in the past decade include 10 vaccines and 11 therapeutic agents in active clinical trials. Maternal vaccination is particularly relevant because the most severe disease occurs within the first 6 months of life, when children are unlikely to benefit from active immunisation. We must optimise the implementation of novel RSV therapeutics by understanding the target populations, showing safety, and striving for acceptable pricing in the context of this worldwide health problem. In this Review, we outline the limitations of RSV LRTI management, the drugs in development, and the remaining challenges related to study design, regulatory approval, and implementation.

AB - Respiratory syncytial virus (RSV) is a major worldwide cause of morbidity and mortality in children under five years of age. Evidence-based management guidelines suggest that there is no effective treatment for RSV lower respiratory tract infection (LRTI) and that supportive care, ie, hydration and oxygenation, remains the cornerstone of clinical management. However, RSV treatments in development in the past decade include 10 vaccines and 11 therapeutic agents in active clinical trials. Maternal vaccination is particularly relevant because the most severe disease occurs within the first 6 months of life, when children are unlikely to benefit from active immunisation. We must optimise the implementation of novel RSV therapeutics by understanding the target populations, showing safety, and striving for acceptable pricing in the context of this worldwide health problem. In this Review, we outline the limitations of RSV LRTI management, the drugs in development, and the remaining challenges related to study design, regulatory approval, and implementation.

UR - http://www.scopus.com/inward/record.url?scp=84960077836&partnerID=8YFLogxK

U2 - 10.1016/S2213-2600(15)00255-6

DO - 10.1016/S2213-2600(15)00255-6

M3 - Literature review

AN - SCOPUS:84960077836

SN - 2213-2600

VL - 3

SP - 888

EP - 900

JO - The Lancet Respiratory Medicine

JF - The Lancet Respiratory Medicine

IS - 11

ER -

Lower respiratory tract infection caused by respiratory syncytial virus: Current management and new therapeutics

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this